The use of low dose methotrexate in rheumatoid arthritis-are we entering a new era of therapeutic drug monitoring and pharmacogenomics?

Biomedicine and Pharmacotherapy

Volumn 60, Issue 10, 2006, Pages 678-687

  Stamp, Lisa ^a,b   Roberts, Rebecca ^a   Kennedy, Martin ^a   Barclay, Murray ^a   O'Donnell, John ^b   Chapman, Peter ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Methotrexate; Methotrexate polyglutamates; Pharmacogenomics; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; FOLINIC ACID; GLUTAMIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; PLACEBO; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; ENZYME; POLYGLUTAMIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CRANIOFACIAL MALFORMATION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG UPTAKE; DRUG WITHDRAWAL; ERYTHROCYTE; FETUS WASTAGE; FOLIC ACID DEFICIENCY; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; HEMATOPOIETIC SUPPRESSION; HUMAN; INFECTION SENSITIVITY; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MEGALOBLASTIC ANEMIA; MUCOSA INFLAMMATION; NAUSEA; PANCYTOPENIA; PHARMACOGENETICS; PHARMACOGENOMICS; PNEUMONIA; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SIDE EFFECT; SPONTANEOUS ABORTION; SUPPLEMENTATION; TERATOGENESIS; THROMBOCYTOPENIA; DOSE RESPONSE; GENETIC POLYMORPHISM; GENETICS; METABOLISM; METHODOLOGY; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ENZYMES; HUMANS; METHOTREXATE; PHARMACOGENETICS; POLYGLUTAMIC ACID; POLYMORPHISM, GENETIC;

EID: 33751401805     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.09.007     Document Type: Article

References (108)

1. Plant M., Jones P., Saklatvala J., Ollier W., and Dawes P. Patterns of radiological progression in early rheumatoid arthritis: results of an 8-year prospective study. J. Rheumatol. 25 3 (1998) 417-426
2. van der Heijde D. Joint erosions and patients with early rheumatoid arthritis. Br. J. Rheumatol. 34 Suppl 2 (1995) 74-78
3. Wolfe F., and Sharp J. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum. 41 9 (1998) 1571-1582
4. Graudal N., Tarp U., Jurik A., et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate and hemoglobin: long-term course and association to radiographic progression. J. Rheumatol. 27 1 (2000) 47-57
5. Wolfe F., and Zwillich S. The long-term outcomes of rheumatoid arthritis. A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis. Arthritis Rheum. 41 6 (1998) 1072-1082
6. Drossaers-Bakker K., de Buck M., van Zeben D., Zwinderman A., Breedveld F., and Hazes J. Long-term course and outcome of functional capacity in rheumatoid arthritis. Arthritis Rheum. 42 9 (1999) 1854-1860
7. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled trial. Lancet 364 (2004) 263-269
8. Sharp J., Strand V., Leung H., Hurley F., Loew-Friedrich I., and The Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum. 43 3 (2000) 495-505
9. Pettit A., Weedon H., Ahern M., et al. Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis. Rheumatol. 40 (2001) 1243-1255
10. Cutolo M., Sulli A., Pizzorni C., Seriolo B., and Straub R. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 60 (2001) 729-735
11. Tishler M., Caspi D., Graff E., Segal R., Peretz H., and Yaron M. Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br. J. Rheumatol. 28 (1989) 422-423
12. Jolivet J., Faucher F., and Pinard M. Influence of intracellular folates on methotrexate metabolism and cytotoxicity. Biochem. Pharmacol. 36 (1987) 3310-3312
13. Kennedy D., van den Berg H., and Clarke R. The effect of leucovorin on the synthesis of methotrexate polygammaglutamates in the MCF-7 human breast cancer cell line. Biochem. Pharmacol. 34 (1985) 2897-2903
14. Arthur A., Klinkhoff A., and Teufel A. Safety of self-injection of gold and methotrexate. J. Rheumatol. 26 2 (1999) 302-305
15. Osman A., and Mulherin D. Is parenteral methotrexate worth trying?. Ann. Rheum. Dis. 60 4 (2001) 432
16. Burbage G., Gupta R., and Lim K. Intramuscular methotrexate in inflammatory rheumatic disease. Ann. Rheum. Dis. 60 (2001) 1156
17. Bingham S., Buch M., Lindsay S., Pollard A., White J., and Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatol. 42 (2003) 1009-1010
18. Wegrzyn J., Adeleine P., and Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann. Rheum. Dis. 63 (2004) 1232-1234
19. Rozin A., Schapira D., Balbir-Gurman A., et al. Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann. Rheum. Dis. 61 (2002) 756-757
20. Hamilton R., and Kremer J. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br. J. Rheumatol. 36 (1997) 86-90
21. Braun J., Kastner P., Flaxenberg P., et al. The clinical efficacy and safety of subcutaneous versus oral application of methotrexate in patients with active rheumatoid arthritis-results of a randomised, controlled, double-blind multicenter study. Arthritis Rheum. 52 9 Suppl (2005) S542
22. Lambert C., Sandhu S., Lochead A., Hurst N., McRorie E., and Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate. Arthritis Rheum. 50 2 (2004) 364-371
23. Brooks P., Spruill W., Parish R., and Birchmore D. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum. 33 1 (1990) 91-94
24. Jundt J., Browne B., Fiocco G., Steele A., and Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J. Rheumatol. 20 (1993) 1845-1849
25. Hoekstra M., Haagsma C., Neeg C., Proost J., Knuif A., and Van de Laar M. Splitting high dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J. Rheumatol. 33 (2006) 481-485
26. Anderson P., West S., O'Dell J., Via C., Claypool R., and Kotzin B. Weekly pulse methotrexate in rheumatoid arthritis. Ann. Intern. Med. 103 4 (1985) 489-496
27. Williams H., Willkens R., Samuelson C., et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 28 7 (1985) 721-730
28. Kremer J., and Phelps C. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum. 35 2 (1992) 138-145
29. Drosos A.T., Tsiakou E., Timpanidou M., et al. Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty month prospective study. Clin Exp Rheumatol 15 3 (1997) 263-267
30. Strand V., Tugwell P., Bombardier C., et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum. 42 9 (1999) 1870-1878
31. Tugwell P., Bombardier C., Buchanan W., et al. Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualised patient preference health status questionnaires. Arch. Intern. Med. 150 (1990) 59-62
32. O'Dell J., Haire C., Erikson N., et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hyroxychloroquine or a combination of all three medications. N. Engl. J. Med. 334 20 (1996) 1287-1291
33. Lehman A., Esdaile J., Klinkhoff A., Fitzgerald A., and Canvin J. A 48-week, randomized, double-blind, double-observer, placebo controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis. Arthritis Rheum. 52 5 (2005) 1360-1370
34. Kremer J., Genovese M., Cannon G., et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann. Intern. Med. 137 (2002) 726-733
35. Klareskog L., Van der Heijde D., de Jager J., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
36. Lipsky P., Van der Heijde D., St Clair E., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1594-1602
37. Weinblatt M., Keystone E., Furst D., et al. Adalimumab, a fully humanised anti-tumor necrosis factor α monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum. 48 1 (2003) 35-45
38. Morand E., McCloud P., and Littlejohn G. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J. Rheumatol. 19 5 (1992) 704-708
39. Suarez-Almazor M., Belseck E., Shea B., Wells G., and Tugwell P. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 2 (2000) CD000952
40. Alarcon G., Tracey I., and Blackburn W. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 32 6 (1989) 671-676
41. Weinblatt M., Kaplan H., Germain B., et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum. 37 10 (1994) 1492-1498
42. Maetzel A., Wong A., Strand V., Tugwell P., Wells G., and Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatol. 39 (2000) 975-981
43. Schnabel A., and Gross W. Low-dose methotrexate in rheumatic diseases-efficacy, side effects, and risk factors for side effects. Semin. Arthritis Rheum. 23 5 (1994) 310-327
44. Gutierrez-Urena S., Molina J., Garcia C., Cuellar M., and Espinoza L. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 39 2 (1996) 272-276
45. Weinblatt M., and Fraser P. Elevated mean corpuscular volume as a predictor of haematologic toxicity due to methotrexate therapy. Arthritis Rheum. 31 12 (1989) 1592-1596
46. Bjorheim J., and Ekstrom P. Review of denaturant capillary electrophoresis in DNA variation analysis. Electrophoresis 26 (2005) 2520-2530
47. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54 3 (2006) 692-701
48. Kremer J., Lee R., and Tolman K. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum. 32 2 (1989) 121-127
49. Suzuki Y., Uehara R., Tajima C., et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low dose methotrexate. Scand J Rheum 28 (1999) 273-281
50. Whiting-O'Keefe Q., Fye K., and Sack K. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. 90 (1991) 711-716
51. Walker A., Funch D., Dreyer N., et al. Determinants of serious liver disease among patients receiving low dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 36 3 (1992) 329-335
52. Kremer J., Alarcon G., Lightfoot R., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 37 3 (1994) 316-328
53. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 46 2 (2002) 328-346
54. Barrera P., Laan R., Van Riel P., Dekhuijzen P., Boerbooms A., and Van de Putte L. Methotrexate related pulmonary complications in rheumatoid arthritis. Ann. Rheum. Dis. 53 (1994) 434-439
55. Kremer J., Alarcon G., Weinblatt M., et al. Clinical, laboratory, radiographic and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. Arthritis Rheum. 40 10 (1997) 1829-1837
56. Grove M., Hassell A., Hay E., and Shadforth M. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. Q. J. Med. 94 (2001) 309-319
57. Saravanan V., and Kelly C. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatol. 43 (2004) 143-147
58. Alarcon G., Kremer J., Macaluso M., et al. Risk factors for methotrexate induced lung disease in patients with rheumatoid arthritis: a multicentre, case-controlled study. Ann. Intern. Med. 127 (1997) 356-364
59. Searles G., and McKendry R. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and review of the literature. J. Rheumatol. 14 (1987) 1164-1171
60. Imokawa S., Colby T., Leslie K., and Helmers R. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur. Respir. J. 15 (2000) 373-381
61. Weinblatt M., Weissman B., Holdsworth D., et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis 84-month update. Arthritis Rheum. 35 2 (1992) 129-137
62. Kerstens P., Boerbooms A., Jeurissen M., Fast J., Assmann K., and van de Putte L. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. J. Rheumatol. 19 6 (1992) 867-871
63. Merrill J., Shen C., Schreibman D., et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 40 7 (1997) 1308-1315
64. Creinin M., Stewart-Akers A., and DeLoia J. Methotrexate effects on trophoblast and the corpus luteum in early pregnancy. Am J Obstet. Gynecol. 179 3 pt 1 (1998) 604-609
65. Ostensen M., Hartmann H., and Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J. Rheumatol. 27 (2000) 1872-1875
66. Morgan S., Baggott J., Vaughn W., et al. The effect of folic acid supplementation of the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 33 1 (1990) 9-18
67. Ortiz Z., Shea B., Suarez-Almazor M., Moher D., Wells G., and Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta analysis of randomized controlled trials. J. Rheumatol. 25 1 (1998) 36-43
68. Ortiz Z., Moher D., Shea B., Suarez-Almazor M., Tugwell P., and Wells G. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. 2 (2000) CD000951
69. Morgan S., Baggott J., Vaughn W., et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann. Intern. Med. 121 11 (1994) 833-841
70. Griffith S., Fisher J., Clarke S., et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?. Rheumatol. 39 (2000) 1102-1109
71. van Ede A., Laan R., Rood M., et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum. 44 7 (2001) 1515-1524
72. Hoekstra M., Van Ede A., Haagsma C., et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62 (2003) 423-426
73. Kent P., Luthra H., and Michet C. Risk factors for methotrexate induced abnormal monitoring results in patients with rheumatoid arthritis. J. Rheumatol. 31 (2004) 1727-1731
74. Moisa A., Fritz P., Benz D., and Wehner H.-D. Iatrogenically-related fatal methotrexate intoxication: a series of four cases. Forensic Sci. Int. 156 (2006) 154-157
75. Sosin M., and Handa S. Low dose methotrexate and bone marrow suppression. BMJ 326 (2003) 266-267
76. Morgan S., Baggott J., Alarcon G., and Koopman W. Folic acid and folinic acid supplementation during low dose methotrexate therpay for rheumatoid arthritis: comment on article by van Ede et al. Arthritis Rheum 46 5 (2002) 1413-1414
77. Khanna D., Park G., Paulus H., et al. Reduction in efficacy of methotrexate by the use of folic acid. Post hoc analysis from two randomised controlled studies. Arthritis Rheum. 52 10 (2005) 3030-3038
78. Dervieux T., Furst D., Lein D., et al. Pharmacogenetic and metabolite measurements are associated with clinical status in rheumatoid arthritis patients treated with methotrexate: results of a multicentered cross sectional observational study. Ann. Rheum. Dis. 64 (2005) 1180-1185
79. Furst D., Koehnke R., Burmeister L., Kohler J., and Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J. Rheumatol. 16 (1989) 313-320
80. Seidman P. Preliminary report: methotrexate-the relationship between dose and clinical effect. Br. J. Rheumatol. 32 (1993) 751-753
81. Dervieux T., Furst D., Lein D., et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50 9 (2004) 2766-2774
82. Lafforgue P., Monjanel-Mouterde S., Durand A., Catalin J., and Acquaviva P. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J. Rheumatol. 22 5 (1995) 844-849
83. Angelis-Stoforidis P., Vajda F., and Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol. 17 (1999) 313-320
84. Kremer J., Lein D., Meyer G., et al. Measurement of erythrocyte methotrexate polyglutamates predicts response to methotrexate therapy in a dose escalation study with rheumatoid arthritis patients. Arthritis Rheum. 50 Suppl (2004) 350
85. Koch W. Technology platforms for pharmacogenomic diagnostic assays. Nature Rev 3 (2004) 749-761
86. Chan E. Advances in sequencing technology. Mutat. Res. 573 (2005) 13-40
87. Ranganathan P., and McLeod H. Methotrexate pharmacogenetics. The first step towards individualised therapy in rheumatoid arthritis. Arthritis Rheum. 54 5 (2006) 1366-1377
88. Weisman M., Furst D., Park G., et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate related side effects in rheumatoid arthritis. Arthritis Rheum. 54 2 (2006) 607-612
89. Ranganathan P., Culverhouse R., Marsh S., et al. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics 5 5 (2004) 559-569
90. Hughes L., Beasley T., Patel H., et al. Racial/ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence in response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65 9 (2006) 1213-1218
91. Dervieux T., Kremer J., Lein D.O., et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14 11 (2004) 733-739
92. Pawlik A., Wrzesniewska J., Fiedorowicz-Fabrycy I., and Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 42 9 (2004) 496-503
93. Hulot J.S., Villard E., Maguy A., et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet. Genomics 15 5 (2005) 277-285
94. van Ede A., Laan R., Blom H., et al. The C677T mutation in the methylenetetrahydrofolate reductase gene. A risk factor for methotrexate-related elevation of liver emzymes in rheumatoid arthritis patients. Arthritis Rheum. 44 11 (2001) 2525-2530
95. Wessels J., de Vries-Bouwstra J., Heijmans B., et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54 4 (2006) 1087-1095
96. Speletas M., Papadopoulos N., Daiou C., Katodritou E., Pavlitou-Tsiontsi A., and Galanopoupou V. Relationship between 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism and methotrexate related toxicity in patients with autoimmune diseases receiving folic acid supplementation. Ann. Rheum. Dis. 64 (2005) 1791-1792
97. Chiusolo P., Reddiconto G., Casorelli I., et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol. 13 12 (2002) 1915-1918
98. Ulrich C.M., Yasui Y., Storb R., et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98 1 (2001) 231-234
99. Urano W., Taniguchi A., Yamanaka H., et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12 3 (2002) 183-190
100. Kumagai K., Hiyama K., Oyama T., Maeda H., and Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med. 11 (2003) 593-600
101. Berkun Y., Levartovsky D., Rubinow A., et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis. 63 (2004) 1227-1231
102. Mandola M.V., Stoehlmacher J., Zhang W., et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 5 (2004) 319-327
103. Goto Y., Yue L., Yokoi A., et al. A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res. 7 7 (2001) 1952-1956
104. Chave K.J., Ryan T.J., Chmura S.E., and Galivan J. Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene 319 (2003) 167-175
105. de Jonge R., Hooijberg J.H., van Zelst B.D., et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 106 2 (2005) 717-720
106. Heil S., Van der Put N., Waas E., den Heijer M., Trijbels F., and Blom H. Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects?. Mol. Genet. Metab. 73 2 (2001) 164-172
107. Felson D., Anderson J., Boers M., et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38 (1995) 727-735
108. Van Gestel A., Prevoo M., van't Hof M., van Rijswijk M., Van de Putte L., and Van Riel P. Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum. 39 1 (1996) 34-40